drugset / Trial / NCT06170476

A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in PONV

NCT06170476

Completed 200 enrolled Sichuan Provincial People's Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Dose-Finding study. About 200 subjects undergoing elective laparoscopic abdominal or gynecological surgery are planned to be enrolled and randomized into four groups by a ratio of 1:1:1:1.

Timeline

Start
2023-11-10
Primary completion
2024-02-28
Completion
2024-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK21542 Peptide 60 ug Intravenous
Subject HSK21542 Peptide 120 ug Intravenous
Subject HSK21542 Peptide 180 ug Intravenous

Indications

No indication recorded.